

Accompanying Documents

Accompanying this response are the following documents:

- (1) A copy of the currently pending claims, incorporating the amendments made herein;
- (2) A Terminal Disclaimer;
- (3) Sequence Listing and Request to Use Computer Readable Form From Another Application.

Amendment

In the Claims:

Please amend claim 37 as follows:

E1
D1

37. (Amended) A chimeric protein comprising a leukotoxin polypeptide [capable of activating] that activates helper T-cells, coupled to a selected [antigen] peptide hormone which is not a cytokine, wherein said leukotoxin polypeptide is an RTX leukotoxin from a bacterium selected from the group consisting of *Pasteurella haemolytica*, *E. coli* and *Actinobacillus pleuropneumoniae*.

Please cancel claims 38, 39, 42 and 43 without prejudice and without disclaimer.

Remarks

Claims 37, 40, 41, 44 and 45 were examined in the Office Action dated August 6, 1999 and rejected based on (1) 35 USC §112, second paragraph; (2) 35 USC §102(b); and (3) 35 USC §103. Additionally, the claims were rejected under the judicially created doctrine of obviousness-type double patenting.

These rejections are believed to be overcome in part by the above amendments and are otherwise traversed for the reasons discussed below.